Skip to main navigation
Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® for Dry AMD
    • OPC1
    • VAC2
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxy Information
      • 2018 AgeX and Form 10 Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu
  • Investors

    Lineage is a clinical-stage biotechnology company developing novel cell therapies

Investors

NYSE AMERICAN: LCTX

Data Provided by Refinitiv. Minimum 15 minutes delayed.

 
VIEW STOCK QUOTE
Press Releases
March 20, 2023
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
March 09, 2023
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 06, 2023
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
VIEW PRESS RELEASES
Events & Presentations
Lineage Cell Therapeutics Corporate Overview January 23, 2023 5.4 MB
Roche’s Pharma Day 2022
Fourth Quarter 2022 Financial Results Earnings Call
Mar 9, 2023 at 4:30 PM EST
Click here for webcast
VIEW EVENTS & PRESENTATIONS
© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   contact@lineagecell.com
  • Facebook
  • Twitter
  • RSS Feed
  • Email Alerts
Scroll to top